NCT05604755

Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT

Effect of Prophylactic HQP1351 Maintenance Post-transplants on Ph+ Luekemia Undergoing Allo-HSCT With MRD Positive Pre-transplants

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: xuna · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and BC-CML. Relapse remains a major cause of treatment failure even after allo-HSCT. The prevention of relapse is essential for improving the outcome of Ph+ ALL. Pre-emptive tyrosine kinase inhibitor (TKIs) administration based on minimal residual disease (MRD) and BCR-ABL mutation after allo-HSCT might reduce the incidence of relapses and improve survival for patients with Ph+ luekemia. In this study, we will evaluate the safety and efficacy of newly third TKI-HQP1351 therapy post-transplants on Ph+ leukemia after allo-HSCT with MRD positive pre-transplants.

Conditions

• Prophylactic HQP1351 Therapy
• Third Generation TKI

Interventions

Type	Name	Description
DRUG	HQP1351( Olverembatinib dimesylate)	HQP1351 was initiated at a dose of 40mg every two days

Timeline

• Start date: 2022-01-01
• Primary completion: 2023-12-30
• Completion: 2024-12-30
• First posted: 2022-11-03
• Last updated: 2023-01-18

Locations

1 site across 1 country: China